# OrSense

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/orsense

- Industry: Medical Devices & Equipment
- Headquarters: Tel Aviv-Yafo, Israel
- Website: www.orsense.com
- Total disclosed funding: $11M
- Latest round: Series C (Aug 14, 2001)
- Investors on record: 3

## About

OrSense Ltd. develops advanced non-invasive medical devices for anemia testing and blood analyte monitoring, enhancing patient care in healthcare settings. Their innovative technology offers efficient solutions in blood donation and monitoring processes.OrSense Ltd. specializes in non-invasive medical devices with a focus on anemia testing and blood analyte monitoring. Founded in 1997 and headquartered in Tel Aviv-Yafo, Israel, the company has undergone multiple funding rounds, with the latest being a Growth round in May 2011, raising USD 18.00 mn from investors including Israel Healthcare Ventures, STAR Ventures, and Lewis Trust Group. The company has completed a total of 7 deals to date.OrSense Ltd. specializes in non-invasive medical devices designed primarily for anemia testing and blood analyte monitoring. The core product, the NBM200, utilizes occlusion spectroscopy technology to measure important parameters such as Hemoglobin (Hb), Oxygen saturation levels, and Pulse Rate. This device is particularly aimed at healthcare providers, including hospitals and blood donation centers, facilitating painless and efficient screenings for donors and patients. Additionally, the company offers SOLIS, a cloud-based inventory management system that streamlines the delivery process from OrSense to clients and subsequently to the field. Their products are marketed across North America, Europe, and Asia, targeting a diverse client base that includes healthcare professionals and organizations focused on patient care and blood donation.OrSense Ltd. generates revenue through the sale of its flagship products, the NBM200 and the SOLIS system, primarily through a direct-to-business model targeting healthcare institutions and blood banks. Transactions typically involve one-time purchases for the devices and software solutions, with potential subscription fees for ongoing use of the SOLIS system. The company’s emphasis on cost-effective and environmentally friendly solutions positions it as a partner for organizations seeking to improve operational efficiency and patient care.OrSense Ltd. plans to leverage the USD 18.00 mn raised in the Growth round led by Israel Healthcare Ventures to expand its market reach and enhance its product offerings. The company is focused on launching new features for the NBM200 and developing additional non-invasive monitoring devices by 2024. Furthermore, OrSense intends to expand into emerging markets in Asia and Latin America by 2025, aiming to increase its global footprint and cater to a broader range of healthcare providers.

## Funding rounds

- Series C, Aug 14, 2001, $8.2M — STAR Ventures, Israel Healthcare Ventures, Tamar Ventures
- Series B, Jan 1, 1999, $2M — STAR Ventures, Tamar Ventures
- Series A, Apr 1, 1998, $1M — STAR Ventures

## Investors

- STAR Ventures — Series A, Series B, Series C
- Tamar Ventures (https://capitalatlas.ai/funds/tamar-ventures) — Series B, Series C
- Israel Healthcare Ventures (https://capitalatlas.ai/funds/israel-healthcare-ventures) — Series C